On the efficiency of treatment of wet age-related macular degeneration with Lucentis

On the efficiency of treatment of wet age-related macular degeneration with Lucentis

The paper studies the efficiency of ranibizumab (Lucentis, Novartis Pharma), a VEGF blocker inhibiting angiogenesis, in patients with wet age macular degeneration (AMD) at different stages of the pathological process. The research included 21 patients (30 eyes), averagely aged 65.1 ± 1.3 years. Intr...

Full description

Bibliographic Details
Main Authors:	E. M. Kasimov, A. M. Shakhmaliyeva, B. H. Gadzhiyeva
Format:	Article
Language:	Russian
Published:	Real Time Ltd 2018-10-01
Series:	Российский офтальмологический журнал
Subjects:	влажная форма возрастной макулярной дегенерации ингибитор ангиогенеза wet form of age macular degeneration angiogenesis inhibitor
Online Access:	https://roj.igb.ru/jour/article/view/23

Similar Items

The efficiency of surgical and laser treatment of the age-related macular degeneration wet form
by: Yu. I. Khoroshikh, et al.
Published: (2011-08-01)

ALGORITHM OF DIAGNOSTICS AND TREATMENT OF AN AGE-RELATED MACULAR DEGENERATION AT PATIENTS WITH CHRONIC PERIPHERAL UVEITIS
by: Yu. I. Khoroshikh, et al.
Published: (2014-02-01)

Сlinical, functional and morphological results of diabetic macular edema antiangiogenic treatment in patients with diabetes mellitus type two
by: L. K. Moshetova, et al.
Published: (2014-07-01)

Applying Lucentis for the treatment of retinopathy of prematurity
by: S. V. Lesovoy, et al.
Published: (2022-12-01)

Сlinical analysis of the series of A-VEGF therapy in patients with retinal pigment epithelium tear complicating of wet form age-related macular degeneration
by: E. V. Kozina, et al.
Published: (2021-10-01)

A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
by: Rufino Silva, et al.
Published: (2017-06-01)

A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
by: Nagpal Manish, et al.
Published: (2007-01-01)

Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration
by: Dawei Zhang, et al.
Published: (2019-01-01)

Curative effect of different drugs in treatment of senile wet macular degeneration
by: Zhi-Qin Zhang, et al.
Published: (2017-06-01)

Small choroidal melanoma and pseudomelanomas: methods of differential diagnostics. Part 1
by: E. B. Myakoshina
Published: (2019-12-01)

Ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration
by: Jia Li, et al.
Published: (2014-10-01)

Research progress in gene therapy for wet age-related macular degeneration
by: Yi Zhang, et al.
Published: (2020-03-01)

Research progress on risk factors of wet age-related macular degeneration
by: Meng Wang, et al.
Published: (2018-09-01)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
by: Agnieszka Nowosielska
Published: (2019-10-01)

Preliminary study of Conbercept injected intravitreally for the treatment of wet age-related macular degeneration
by: Ying Qin, et al.
Published: (2017-08-01)

Dry age-related macular degeneration - therapeutic possibilities and research directions
by: Alicja Zajdel
Published: (2022-10-01)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
by: Avaylon J, et al.
Published: (2020-05-01)

Comparison of efficacy between Ranibizumab and Conbercept for wet age-related macular degeneration
by: Qiang Fan, et al.
Published: (2018-08-01)

Mongolian medicine Mingmu-11 Pills combined with Conbercept in the treatment of wet age-related macular degeneration
by: Su Riguga, et al.
Published: (2024-05-01)

Study progress of CCR3 in wet age-related macular degeneration
by: Xian-Wei Wu, et al.
Published: (2014-03-01)

Recent advances in treatment of wet age-related macular degeneration
by: Ming Li, et al.
Published: (2015-02-01)

Clinical observation of Conbercept in the treatment of patients with wet age-related macular degeneration
by: Si Zhang, et al.
Published: (2020-05-01)

Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs
by: Małgorzata Figurska, et al.
Published: (2021-12-01)

Various doses of statins and coronary angiogenesis in patients with coronary heart disease
by: I. V. Sergienko, et al.
Published: (2009-10-01)

Diurnal variation of optical coherence tomography–based macular fluid in exudative age-related macular degeneration
by: Blake H. Fortes, et al.
Published: (2023-09-01)

OCT-Derived Radiomic Features Predict Anti–VEGF Response and Durability in Neovascular Age-Related Macular Degeneration
by: Sudeshna Sil Kar, PhD, et al.
Published: (2022-12-01)

Microcurrent stimulation in the treatment of dry and wet macular degeneration
by: Chaikin L, et al.
Published: (2015-12-01)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
by: Francisco Jose Rodriguez, et al.
Published: (2019-01-01)

Current advance in the application of anti-vascular endothelial growth factor drugs in wet age-related macular degeneration
by: Ling-Yi Ouyang, et al.
Published: (2020-01-01)

OCTA in evaluating therapeutic effect of wet age-related macular degeneration
by: Liang Wang, et al.
Published: (2020-06-01)

Recent Advances in Age-Related Macular Degeneration Therapies
by: Marie Fabre, et al.
Published: (2022-08-01)

Changes of retinal structure in macular region after treatment with Conbercept for wet age-related macular degeneration
by: Ping-Ping Liu, et al.
Published: (2020-02-01)

Meta-analysis of diagnostic value of OCTA for choroidal neovascularization of wet age-related macular degeneration
by: Shuang Liu, et al.
Published: (2021-07-01)

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
by: Shashikant Sharma, et al.
Published: (2021-03-01)

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration
by: S. V. Nedogoda, et al.
Published: (2020-03-01)

Mechanism of mingjing granules in treating wet age-related macular degeneration based on network pharmacology and experimental verification
by: Xiao-Yu Li, et al.
Published: (2024-01-01)

One-year outcomes of resveratrol supplement with aflibercept versus aflibercept monotherapy in wet age-related macular degeneration
by: Ioannis Datseris, et al.
Published: (2023-09-01)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021-09-01)

Switching therapy in patients with age-related macular degeneration, diabetic macular edema and cistoid macular edema due to retinal vein occlusion
by: Dijana Risimić, et al.
Published: (2019-06-01)

Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration
by: Mikael Kähkönen, et al.
Published: (2021-08-01)